选择性α_1受体阻滞剂治疗前列腺增生的尿动力学研究

Urodynamic change in the treatment of benign prostatic hyperplasia with terazosin

用选择性α１肾上腺素能受体阻滞剂盐酸四喃唑嗪（商品名高特灵）治疗有症状ＢＰＨ患者，并用非选择性ａ受体阻滞剂酚苄明和安慰剂作对照治疗。３０例患者随机分为三组，每组１０例，实验组用高特灵４ｍｇ／ｄ，对比治疗组用酚苄明２０ｍｇ／ｄ，对照组用安慰剂２片／ｄ，均３周为一个疗程。结果表明：两种药物均能明显改善排尿困难等主观症状，显著增加尿流率（Ｐ＜０．０５），非常显著降低前列腺压（Ｐ＜０．０１），但对于降低膀胱颈压，高特灵优于酚苄明。与酚苄明相比较，高特灵的用药量少、副作用小而轻，对照组服药前后症状及尿动力学检查无显著变化。

patients with symptomatic benign prostatic hyperplasia (BPH) were treated with terazosin (a selective-adrenoceptor blocker) or Zhu Lin An (a non-selective-adrenoceptor blocker). Terazosin (1￣4mg/d )was instituted in 10 and Zhu Lin An (20 mg/d) in another 10 for a course of 3 weeks. Improvement in subjective symptoms and objective urodynamic changes were observed. The results demonstrated that both Terazosin and Zhu Lin An could significantly improve the subjective symptoms, decrease the prostatic pressure(P<0.05) and increase the urinary flow rates (P <0.01). Terazosin (P<0.01) was however better than Zhu Lin An ( P<0.05) in decreasing the pressure at bladder neck and with less adverse side effects. So Terazosin is safe and effective in the treatment of benign prostatic hyperplasia.